KDM1A and melanoma: Notably, the introduction of LSD1/KDM1A inhibition (targeting a H3K4me1/2 and H3K9me1/2 demethylase) in a melanoma mouse model resulted in IFN signaling induction and sensitization to checkpoint inhibition, thus stimulating tumor immunogenicity [155].